Floatz logo

Dabigatran

CADASIL

S. Andrea HospitalPhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

5 Active assets in the CADASIL cohort.

Asset / SponsorPhaseRating
Adrenomedullin
National Cerebral and Cardiovascular Center, Japan
Phase 2B
Hov-12020
Hovid Berhad
Phase 2B
PHYSIOLOGIC SODIUM CHLORIDE SOLUTION
Ever Neuro Pharma GmbH
Phase 2CCC
Cerebrolysin
Ever Neuro Pharma GmbH
Phase 2CCC
Fremanezumab
Mayo Clinic
Phase 2CCC
6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydrocarbostyril
Mayo Clinic
Phase 1/2CCC

Same molecule, other indications

Dabigatran is also rated in:

atrial fibrillationDormant
BBB
Indicative ·
79 / 100
View asset →
atrial flutterDormant
BBB
Indicative ·
78 / 100
View asset →
BleedingDormant
BBB
Indicative ·
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →